LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 16

Search options

  1. Article ; Online: Shoulder Injury Related to Vaccine Administration: Diagnosis and Management.

    Wood, Chelsey T / Ilyas, Asif M

    Journal of hand surgery global online

    2022  Volume 4, Issue 2, Page(s) 111–117

    Abstract: Shoulder injury related to vaccine administration (SIRVA) is a rare but potentially debilitating injury characterized by persistent shoulder pain, typically occurring within 48 hours of intramuscular deltoid vaccine administration. With over 150 million ... ...

    Abstract Shoulder injury related to vaccine administration (SIRVA) is a rare but potentially debilitating injury characterized by persistent shoulder pain, typically occurring within 48 hours of intramuscular deltoid vaccine administration. With over 150 million flu vaccines being administered in the United States each year, and the US Centers for Disease Control's goal of immunizing greater than 70% of the population for the coronavirus disease 2019 virus, cases of SIRVA can be expected to rise. A search of current literature was done to identify published material corresponding to incidence, diagnosis, and treatment of SIRVA. Most events have been associated with poor needle placement and/or a local reaction to the delivered serum during vaccine administration. Shoulder injury related to vaccine administration events can lead to persistent and possibly permanent injury. Clinical evaluation involves a thorough history, physical examination, and often diagnostic studies including radiographs, magnetic resonance imaging, and nerve studies. Treatment is individually directed and should initially consist of observation and local symptom management. Recalcitrant cases or infections may warrant surgical intervention. Published outcomes vary widely, and our understanding of SIRVA remains limited. Large-scale studies are necessary to better understand the pathophysiology of SIRVA, its treatment, and its outcomes. Overall, the initial priority in managing SIRVA should be awareness and prevention.
    Language English
    Publishing date 2022-01-28
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 2589-5141
    ISSN (online) 2589-5141
    DOI 10.1016/j.jhsg.2021.12.009
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: A 52-Year-Old Woman with Abdominal Pain and Vomiting.

    Wood, Chelsey T / Monahan, Brian V / Windom, Carman E / Hamilton, Audrey E / Balinski, Aaron / Ripley-Hager, Charis

    NEJM evidence

    2024  Volume 3, Issue 2, Page(s) EVIDmr2300313

    Abstract: A 52-Year-Old Woman with Abdominal Pain and VomitingA 52-year-old woman presented for evaluation of abdominal pain, nausea, and vomiting after consuming a large calzone. How do you approach the evaluation, and what is the diagnosis? ...

    Abstract A 52-Year-Old Woman with Abdominal Pain and VomitingA 52-year-old woman presented for evaluation of abdominal pain, nausea, and vomiting after consuming a large calzone. How do you approach the evaluation, and what is the diagnosis?
    MeSH term(s) Female ; Humans ; Middle Aged ; Vomiting/diagnosis ; Nausea/diagnosis ; Abdominal Pain/diagnosis ; Diagnosis, Differential
    Language English
    Publishing date 2024-01-23
    Publishing country United States
    Document type Case Reports ; Journal Article
    ISSN 2766-5526
    ISSN (online) 2766-5526
    DOI 10.1056/EVIDmr2300313
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Mechanical and interventional support for heart failure with preserved ejection fraction: A review.

    Gordon, Jonathan S / Blazoski, Cameron M / Wood, Chelsey T / Zuber, Charlotte / Massey, Howard T / Throckmorton, Amy / Tchantchaleishvili, Vakhtang

    Artificial organs

    2022  Volume 46, Issue 11, Page(s) 2109–2117

    Abstract: Introduction: Restrictive cardiomyopathy (RCM) and hypertrophic cardiomyopathy (HCM) are two disease processes that are known to progress to heart failure with preserved ejection fraction (HFpEF). Pharmacologic therapies for HFpEF have not improved ... ...

    Abstract Introduction: Restrictive cardiomyopathy (RCM) and hypertrophic cardiomyopathy (HCM) are two disease processes that are known to progress to heart failure with preserved ejection fraction (HFpEF). Pharmacologic therapies for HFpEF have not improved patient outcomes or reduced mortality in this patient cohort; thus, there continues to be substantial interest in other treatment strategies, including surgical interventions and devices. In this article, we explore and report the current utility of percutaneous therapies and surgically implanted mechanical support in the treatment of patients with HFpEF.
    Results: Treatment strategies include percutaneous interventions with interatrial shunts, left atrial assist devices (LAADs), and ventricular assist devices (VADs) in various configurations. Although VADs have been employed to treat patients with heart failure with reduced ejection fraction, their efficacy is limited in those with RCM and HCM. A left atrial-to-aortic VAD has been proposed to directly unload the left atrium, but data is limited. Alternatively, a LAAD could be placed in the mitral position and simultaneously unload the left atrium, while filling the left ventricle.
    Conclusion: A left atrial assist device in the mitral position is a promising solution to address the hemodynamic abnormalities in RCM and HCM; these pumps, however, are still under development.
    MeSH term(s) Humans ; Heart Failure/surgery ; Stroke Volume ; Heart-Assist Devices/adverse effects ; Heart Ventricles ; Heart Atria
    Language English
    Publishing date 2022-05-17
    Publishing country United States
    Document type Journal Article ; Review
    ZDB-ID 441812-8
    ISSN 1525-1594 ; 0160-564X
    ISSN (online) 1525-1594
    ISSN 0160-564X
    DOI 10.1111/aor.14275
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Infection following CF-LVAD exchange for non-infectious indications: A systematic review and meta-analysis.

    Sukhavasi, Amrita / Blazoski, Cameron M / Maynes, Elizabeth J / Wood, Chelsey T / Weber, Matthew P / O'Malley, Thomas J / Rajapreeyal, Indranee / Massey, H Todd / Tchantchaleishvili, Vakhtang

    The International journal of artificial organs

    2022  , Page(s) 3913988221132293

    Abstract: Introduction: Patients on continuous flow left ventricular assist devices (CF-LVADs) often require CF-LVAD exchange. The purpose of this study was to investigate the incidence of infection following CF-LVAD exchange performed for non-infectious ... ...

    Abstract Introduction: Patients on continuous flow left ventricular assist devices (CF-LVADs) often require CF-LVAD exchange. The purpose of this study was to investigate the incidence of infection following CF-LVAD exchange performed for non-infectious indications.
    Methods: An electronic literature search was performed to identify all studies of patients undergoing CF-LVAD exchange for pump thrombosis or device malfunction. Of 2,698 articles identified, 6 studies with 81 total patients met the inclusion criteria. Cohort-level data were pooled for meta-analysis.
    Results: Mean patient age was 60 years (95% CI: 41-78), and 74% were male (95% CI: 61-84). Pump thrombosis was the most common indication for exchange in 70% of patients (95% CI: 47-86). Other indications were driveline fracture and electrical malfunction in 21% (95% CI: 5-56) and 12% (95% CI: 4-33) of patients, respectively. Prior to exchange, 95% of patients were on HeartMate II (HM2) LVADs (95% CI: 86-98) and average duration of support for these patients was 27.1 months (95% CI: 9.3-44.8). The majority were placed on a HM2 following exchange (88% (95% CI: 45-98)) versus HM3 (12% (95% CI: 2-55)). Follow-up was an average of 16.4 months (95% CI: 6.8-26.0). Following exchange, 16 of 81 patients developed infection, with pooled mean incidence of 24% (95% CI: 14-38). 30-day mortality was 14% (95% CI: 7-26). Survival at follow-up was 65% (95% CI: 52-76).
    Conclusions: Infection following CF-LVAD exchange can occur at rates higher than those observed with primary implantation; therefore, effective strategies need to implemented early and consistently to help lower infections rates and help improve outcomes following exchange.
    Language English
    Publishing date 2022-11-13
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80456-3
    ISSN 1724-6040 ; 0391-3988
    ISSN (online) 1724-6040
    ISSN 0391-3988
    DOI 10.1177/03913988221132293
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Continuous-flow left ventricular assist device implantation in patients with preexisting mechanical mitral valves: a systematic review.

    Gordon, Jonathan S / O'Malley, Thomas J / Maynes, Elizabeth J / Wood, Chelsey T / Kalantri, Neal / Morris, Rohinton J / Samuels, Louis E / Massey, H Todd / Tchantchaleishvili, Vakhtang

    Expert review of medical devices

    2020  Volume 17, Issue 5, Page(s) 399–404

    Abstract: ... ...

    Abstract Introduction
    MeSH term(s) Adult ; Female ; Heart Valve Prosthesis ; Heart-Assist Devices/adverse effects ; Humans ; Male ; Middle Aged ; Mitral Valve/surgery ; Postoperative Complications/etiology ; Prosthesis Implantation ; Risk Factors ; Survival Analysis
    Language English
    Publishing date 2020-04-20
    Publishing country England
    Document type Journal Article ; Systematic Review
    ZDB-ID 2250857-0
    ISSN 1745-2422 ; 1743-4440
    ISSN (online) 1745-2422
    ISSN 1743-4440
    DOI 10.1080/17434440.2020.1754190
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Ventricular arrhythmias following continuous-flow left ventricular assist device implantation: A systematic review.

    Gordon, Jonathan S / Maynes, Elizabeth J / Choi, Jae Hwan / Wood, Chelsey T / Weber, Matthew P / Morris, Rohinton J / Massey, H Todd / Tchantchaleishvili, Vakhtang

    Artificial organs

    2020  Volume 44, Issue 8, Page(s) E313–E325

    Abstract: Ventricular arrhythmias (VA) are not uncommon after continuous-flow left ventricular assist device (CF-LVAD) implantation. In this systematic review, we sought to identify the patterns of VA that occurred following CF-LVAD implantation and evaluate their ...

    Abstract Ventricular arrhythmias (VA) are not uncommon after continuous-flow left ventricular assist device (CF-LVAD) implantation. In this systematic review, we sought to identify the patterns of VA that occurred following CF-LVAD implantation and evaluate their outcomes. An electronic search was performed to identify all articles reporting the development of VA following CF-LVAD implantation. VA was defined as any episode of ventricular fibrillation (VF) or sustained (>30 seconds) ventricular tachycardia (VT). Eleven studies were pooled for the analysis that included 393 CF-LVAD patients with VA. The mean patient age was 57 years [95%CI: 54; 61] and 82% [95%CI: 73; 88] were male. Overall, 37% [95%CI: 19; 60] of patients experienced a new onset VA after CF-LVAD implantation, while 60% [95%CI: 51; 69] of patients had a prior history of VA. Overall, 88% of patients [95%CI: 78; 94] were supported on HeartMate II CF-LVAD, 6% [95%CI: 3; 14] on HeartWare HVAD, and 6% [95%CI: 2; 13] on other CF-LVADs. VA was symptomatic in 47% [95%CI: 28; 68] of patients and in 50% [95%CI: 37; 52], early VA (<30 days from CF-LVAD) was observed. The 30-day mortality rate was 7% [95%CI: 5; 11]. Mean follow-up was 22.9 months [95%CI: 4.8; 40.8], during which 27% [95%CI: 17; 39] of patients underwent heart transplantation. In conclusion, approximately a third of patients had new VA following CF-LVAD placement. VA in CF-LVAD patients is often symptomatic, necessitates treatment, and carries a worse prognosis.
    Language English
    Publishing date 2020-03-08
    Publishing country United States
    Document type Journal Article
    ZDB-ID 441812-8
    ISSN 1525-1594 ; 0160-564X
    ISSN (online) 1525-1594
    ISSN 0160-564X
    DOI 10.1111/aor.13665
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article: Development of malignancies and their outcomes in patients supported on continuous-flow left ventricular assist devices-a systematic review.

    Maynes, Elizabeth J / Gordon, Jonathan S / Weber, Matthew P / O'Malley, Thomas J / Bauer, Tyler M / Wood, Chelsey T / Morris, Rohinton J / Samuels, Louis E / Entwistle, John W / Massey, H Todd / Tchantchaleishvili, Vakhtang

    Annals of cardiothoracic surgery

    2021  Volume 10, Issue 3, Page(s) 301–310

    Abstract: Background: With increased use of continuous-flow left ventricular assist devices (CF-LVAD), development of malignant tumors in this population is not uncommon. We sought to evaluate malignancies in CF-LVAD patients and evaluate the outcomes of ... ...

    Abstract Background: With increased use of continuous-flow left ventricular assist devices (CF-LVAD), development of malignant tumors in this population is not uncommon. We sought to evaluate malignancies in CF-LVAD patients and evaluate the outcomes of treatment strategies.
    Methods: Overall, 18 articles consisting of 28 patients were identified who developed malignancies after CF-LVAD placement. Patient-level data were extracted for systematic review.
    Results: Median patient age was 60 years [59-67] and 85.7% (24/28) were male. CF-LVAD was placed as bridge-to-transplant (BTT) in 60.9% (14/23) of patients. The three most common malignancy types were GI in 35.7% (10/28) of patients, lung in 21.4% (6/28) and skin in 10.7% (3/28). Median time from CF-LVAD implant to malignancy diagnosis was 6.9 [2.5-12.8] months. Metastatic disease occurred in 17.9% (5/28) over a median time of 5.0 [1.0-82.0] months from the diagnosis. Surgical resection of the malignancy was performed in 57.1% (16/28) of patients. Our results showed that while there was a significantly higher probability of survival among patients who underwent surgery versus those who did not, when only stage I and II patients were included in the analysis, this difference was no longer statistically significant. Three patients were relisted for heart transplant after surgical treatment, and two received the transplant.
    Conclusions: Surgical management of malignancies in patients on CF-LVADs may improve survival and transplant eligibility status, therefore, a CF-LVAD should not always preclude surgical treatment.
    Language English
    Publishing date 2021-06-03
    Publishing country China
    Document type Journal Article
    ZDB-ID 2713627-9
    ISSN 2304-1021 ; 2225-319X
    ISSN (online) 2304-1021
    ISSN 2225-319X
    DOI 10.21037/acs-2020-cfmcs-10
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: Tricuspid regurgitation associated with implantable electrical device insertion: A systematic review and meta-analysis.

    Tatum, Rob / Maynes, Elizabeth J / Wood, Chelsey T / Deb, Avijit K / Austin, Melissa A / O'Malley, Thomas J / Choi, Jae Hwan / Massey, H Todd / Morris, Rohinton J / Pavri, Behzad B / Tchantchaleishvili, Vakhtang

    Pacing and clinical electrophysiology : PACE

    2021  Volume 44, Issue 8, Page(s) 1297–1302

    Abstract: Background: Implantable cardioverter defibrillator (ICD) and permanent pacemaker (PPM) lead placement may worsen or result in tricuspid regurgitation (TR). While the association between lead placement and the incidence of TR has been established, ... ...

    Abstract Background: Implantable cardioverter defibrillator (ICD) and permanent pacemaker (PPM) lead placement may worsen or result in tricuspid regurgitation (TR). While the association between lead placement and the incidence of TR has been established, current understanding of this problem remains incomplete. This systematic review and meta-analysis sought to pool the existing evidence to better understand the occurrence and severity of TR associated with cardiac implantable electrical device (CIED) insertion.
    Methods: An electronic search was performed to identify all relevant studies published from 2000 to 2018. Overall, 15 studies were selected for the analysis comprising 4019 patients with data reported on TR development following ICD or PPM lead placement. Demographic information, perioperative clinical variables, and clinical outcome measures, including pre and postoperative echocardiographic TR grade changes, were extracted and pooled for systematic review.
    Results: Mean patient age was 69 years [95% CI: 64.62-73.59], and 63% [95% CI: 57-68] were male. Devices implanted included ICD in 57% [95%CI: 43-70] and PPM in 41% [95%CI: 31-52]. The most common indications for pacemaker implantation were sick sinus syndrome in 22% [95% CI: 22-37] and AV block in 21% [95%CI:12-34. The commonest indications for ICD implantation were primary and secondary prevention of sudden cardiac death. Atrial fibrillation was present in 37% [95%CI: 28-46] and congestive heart failure in 15% [95%CI: 2-57]. Baseline distribution of TR grades were as follows: grade 0/1 TR in 89% [95%CI: 82-93], grade 2 TR in 8% [95%CI: 5-13], grade 3 TR in 2% [95%CI: 0-7] and grade 4 TR in 2% [95%CI: 1-4]. Post-procedure, grade 0/ 1 TR decreased to 68% [95% CI: 51-81] (p < 0.01), grade 2 TR increased to 21% [15-28] (p < 0.01), grade 3 TR increased to 13% [95%CI: 5-32] (p = 0.02), and grade 4 TR increased to 7% [95%CI: 5-9] (p < 0.01).
    Conclusion: ICD and PPM lead placement is associated with increased TR post-procedure. Further studies are warranted to evaluate changes in TR grade in the long term.
    MeSH term(s) Defibrillators, Implantable/adverse effects ; Humans ; Pacemaker, Artificial/adverse effects ; Risk Factors ; Tricuspid Valve Insufficiency/etiology
    Language English
    Publishing date 2021-07-01
    Publishing country United States
    Document type Journal Article ; Meta-Analysis ; Systematic Review
    ZDB-ID 424437-0
    ISSN 1540-8159 ; 0147-8389
    ISSN (online) 1540-8159
    ISSN 0147-8389
    DOI 10.1111/pace.14287
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article: Outcomes of Mechanical Circulatory Support for Giant Cell Myocarditis: A Systematic Review.

    Patel, Preeyal M / Saxena, Abhiraj / Wood, Chelsey T / O'Malley, Thomas J / Maynes, Elizabeth J / Entwistle, John W C / Massey, H Todd / Pirlamarla, Preethi R / Alvarez, René J / Cooper, Leslie T / Rame, J Eduardo / Tchantchaleishvili, Vakhtang

    Journal of clinical medicine

    2020  Volume 9, Issue 12

    Abstract: Treatment of giant cell myocarditis (GCM) can require bridging to orthotopic heart transplantation (OHT) or recovery with mechanical circulatory support (MCS). Since the roles of MCS and immunotherapy are not well-defined in GCM, we sought to analyze ... ...

    Abstract Treatment of giant cell myocarditis (GCM) can require bridging to orthotopic heart transplantation (OHT) or recovery with mechanical circulatory support (MCS). Since the roles of MCS and immunotherapy are not well-defined in GCM, we sought to analyze outcomes of patients with GCM who required MCS. A systematic search was performed in June 2019 to identify all studies of biopsy-proven GCM requiring MCS after 2009. We identified 27 studies with 43 patients. Patient-level data were extracted for analysis. Median patient age was 45 (interquartile range (IQR): 32-57) years. 42.1% (16/38) were female. 34.9% (15/43) presented in acute heart failure. 20.9% (9/43) presented in cardiogenic shock. Biventricular (BiVAD) MCS was required in 76.7% (33/43) of cases. Of the 62.8% (27/43) of patients who received immunotherapy, 81.5% (22/27) used steroids combined with at least one other immunosuppressant. Cyclosporine was the most common non-steroidal agent, used in 40.7% (11/27) of regimens. Immunosuppression was initiated before MCS in 59.3% (16/27) of cases, after MCS in 29.6% (8/27), and not specified in 11.1% (3/27). Immunosuppression started prior to MCS was associated with significantly better survival than MCS alone (
    Language English
    Publishing date 2020-12-01
    Publishing country Switzerland
    Document type Journal Article
    ZDB-ID 2662592-1
    ISSN 2077-0383
    ISSN 2077-0383
    DOI 10.3390/jcm9123905
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article ; Online: Survival outcomes of stenting outflow graft stenosis in continuous-flow left ventricular assist devices: a systematic review.

    Wood, Chelsey T / O'Malley, Thomas J / Maynes, Elizabeth J / Vishnevsky, Alec / Morris, Rohinton J / Samuels, Louis E / Massey, H Todd / Tchantchaleishvili, Vakhtang

    Heart failure reviews

    2019  Volume 25, Issue 6, Page(s) 985–992

    Abstract: Stenosis in the continuous-flow left ventricular assist device (CF-LVAD) outflow graft is caused by various factors. We discuss indications for percutaneous intervention of outflow graft complications and evaluate the use of this treatment in re- ... ...

    Abstract Stenosis in the continuous-flow left ventricular assist device (CF-LVAD) outflow graft is caused by various factors. We discuss indications for percutaneous intervention of outflow graft complications and evaluate the use of this treatment in re-establishing adequate CF-LVAD flow. An electronic search was performed to identify all studies in the English literature reporting CF-LVAD outflow graft stenting. Twenty-one studies consisting of 26 patients were included. Patient-level data were extracted for statistical analysis. Median patient age was 59 years [45.8-67.0] and 65.4% (17/26) were male. 58.3% (14/24) of patients had HeartWare HVAD, 37.5% (9/24) had HeartMate II LVAD, and 4.2% (1/24) had HeartMate III LVAS. Median time from device placement to outflow graft stenting was 24.0 months [7.8-30.4]. 76.9% of patients (20/26) presented with heart failure. Complications of the CF-LVAD outflow graft included thrombosis in nine patients (34.6%), stenosis in nine patients (34.6%), kinking in three patients (11.5%), pseudoaneurysm in one patient (3.8%), external graft compression in one patient (3.8%), and bronchial-arterial fistula in one patient (3.6%). Immediate flow improvement occurred in 23/26 patients (88.5%), with the remaining 11.5% (3/26) requiring additional procedures. Pre- and post-intervention flows were 2.9 L/min [2.0-3.5] and 4.7 L/min [4.1-4.8] respectively (p = 0.01). Of patients, 96.2% (25/26) were discharged with a median time to discharge of 4 days [3.0-5.0]. The 30-day mortality was 6.7% (1/15). Overall mortality during the median follow-up of 90 days was 9.5% (2/21). Outflow graft stenting appears to effectively alleviate CF-LVAD outflow graft obstruction and is associated with low overall mortality.
    MeSH term(s) Constriction, Pathologic/mortality ; Global Health ; Heart Failure/physiopathology ; Heart Failure/surgery ; Heart Ventricles/physiopathology ; Heart-Assist Devices/adverse effects ; Humans ; Postoperative Complications/mortality ; Prosthesis Failure ; Stents/adverse effects ; Survival Rate/trends
    Language English
    Publishing date 2019-12-06
    Publishing country United States
    Document type Journal Article ; Systematic Review
    ZDB-ID 1336499-6
    ISSN 1573-7322 ; 1382-4147
    ISSN (online) 1573-7322
    ISSN 1382-4147
    DOI 10.1007/s10741-019-09888-w
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top